KRRO Nasdaq· Korro Bio Inc.
FundamentalsNews digest Peer analysis
KRRO Nasdaq· Korro Bio Inc.
Earnings report Q3 2023

KRRO Reports Declining Revenue in Latest Quarter

Segments of Revenue

In the latest quarter, KRRO reported a decline in revenue across its segments. The company's revenue primarily comes from private and public securities financings, a term loan, and amounts received under a collaboration agreement. However, specific details regarding the revenue breakdown for each segment were not provided in the report.


Despite the decline in revenue, KRRO's management highlighted its ongoing merger agreement with Korro Bio, Inc. as a strategic move to enhance the company's business. The merger is expected to result in Korro Bio becoming a wholly owned subsidiary of KRRO, potentially bringing new opportunities and synergies to the combined company.


KRRO faced challenges in the latest quarter, as evidenced by the declining revenue. The report did not provide specific reasons for the revenue decline, but it is worth noting that the company has been incurring recurring losses since its inception. This indicates ongoing financial challenges that may have contributed to the decline in revenue.


The report mentioned a reduction in force of approximately 55% of KRRO's workforce, which was announced on May 31, 2023. This workforce reduction was aimed at aligning the company's workforce with its business needs. Additionally, KRRO incurred costs related to this restructuring, including severance costs and related expenses.


KRRO reported declining revenue in the latest quarter, with specific details about segment revenues not provided. The company's ongoing merger agreement with Korro Bio, Inc. was highlighted as a potential strength, while the recurring losses and workforce reduction posed challenges. The decline in revenue may be attributed to the company's financial challenges and ongoing restructuring efforts.

Source documents

Form 10-Q  filed on Nov 02, 2023
18 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by -∞%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.